POTP Point Therapeutics (MM)

Point Therapeutics, Inc. (NASDAQ: POTP) today announced that because of his other commitments and responsibilities, William J. Whelan, Jr. has resigned from the Company�s Board of Directors. Mr. Whelan has served on the Board since 1997. �We are very grateful for Bill�s contributions, advice, and counsel in his 10 years of service to Point, and I am joined by the other directors in wishing him very well,� said Don Kiepert, President, Chairman, and CEO of Point Therapeutics. About Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical company which is currently studying its lead product candidate, talabostat, in two Phase 3 double blind placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.